ERA

Download the full-sized PDF of Silencing immunoglobulin gene enhancers as a potential treatment strategy for multiple myelomaDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3V06W

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

Silencing immunoglobulin gene enhancers as a potential treatment strategy for multiple myeloma Open Access

Descriptions

Other title
Subject/Keyword
IgH enhancers
multiple myeloma
translocations
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Toman, Inka
Supervisor and department
Reiman, Tony (Oncology)
Hitt, Mary (Oncology)
Examining committee member and department
McDermid, Heather (Biological Sciences)
Department
Department of Oncology
Specialization

Date accepted
2009-06-25T15:30:31Z
Graduation date
2009-11
Degree
Master of Science
Degree level
Master's
Abstract
Multiple myeloma is a bone marrow malignancy characterized by the presence of monoclonal plasma cells. In 50-75% of myeloma patients, chromosome translocations at the IgH locus are observed, which result in overexpression of oncogenes from the translocated chromosome due to linkage with the IgH enhancers. IgH enhancer activity is mediated by the B cell-specific transcription factors Bob1 and Oct2. We hypothesized that inhibiting the IgH enhancer, through inhibition of Bob1 and Oct2, is a potential therapeutic strategy for translocation-positive myeloma. The expression and prognostic value of Bob1 and Oct2 in myeloma patient samples were assayed. High Bob1 expression was associated with increased survival, whereas high Oct2 expression was associated with reduced survival. In a t(4;14) myeloma cell line, Bob1 inhibition led to decreased expression of the translocated oncogene, FGFR3; however, this did not lead to decreased proliferation or increased apoptosis. To fully understand the roles of Bob1 and Oct2 in myeloma, further research is required.
Language
English
DOI
doi:10.7939/R3V06W
Rights
Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication

File Details

Date Uploaded
Date Modified
2014-05-01T02:47:18.450+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 4921739
Last modified: 2015:10:12 12:53:07-06:00
Filename: Toman_Inka_Fall 2009.pdf
Original checksum: d69e6fc628f18e2634915fba69c8cea8
Well formed: true
Valid: true
File title: Toman_Inka_Fall 2009
File title: Exam Committee
Page count: 173
Activity of users you follow
User Activity Date